Lymphomas & Lymphoid Neoplasia

A collection of features and news articles published in ASH Clinical News related to lymphomas and lymphoid neoplasia.

Prognostic Significance of Post-Transplant MRD Varies Based on Conditioning Regimen in ALL

Assessment of measurable residual disease (MRD) prior to allogeneic hematopoietic cell transplantation (alloHCT) is an established important prognostic factor in patients with acute lymphocytic...

Are CAR T-Cell Therapies Moving to Hodgkin Lymphoma?

Results from two studies presented at the 2019 Transplantation & Cellular Therapy Meetings suggest that Hodgkin lymphoma (HL) may be the next target for...

Adoptive “Non-Engineered” T-Cell Therapy Shows Preliminary Efficacy in Lymphomas

Chimeric antigen receptor (CAR) T-cell therapies engineered to recognize and destroy CD19 antigens on the surface of lymphoma cells have revolutionized the treatment of...

Adolescent and Young Adult Cancer Survivors Face Higher Risk of Second Cancers

People who were diagnosed with cancer as adolescents or young adults (AYAs) have an excess risk of developing a subsequent primary neoplasm later in...

Patient With HIV and Hodgkin Lymphoma Is Virus-Free Following Transplant

An allogeneic hematopoietic cell transplantation (alloHCT) intended to cure a patient’s refractory Hodgkin lymphoma (HL) may have also put his HIV virus into remission,...

Medicare Poised to Cover CAR T-Cell Therapy

Medicare may soon offer coverage of chimeric antigen receptor (CAR) T-cell therapy for patients with cancer, but with considerable restrictions that aim to rein...
WIB_icon

Evaluating Thalidomide-Cyclophosphamide-Prednisone for Idiopathic Multicentric Castleman Disease

An oral combination of thalidomide, cyclophosphamide, and prednisone (TCP) induced durable tumor and symptomatic response rates in nearly half of patients with newly diagnosed...

JULIET Analysis Finds Durable Responses With Tisagenlecleucel in DLBCL

Half of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) responded to tisagenlecleucel, and approximately two-thirds of responders are expected to remain...

Ibrutinib and Obinutuzumab Combo Granted Approval for CLL/SLL

The U.S. Food and Drug Administration (FDA) approved the combination of ibrutinib and obinutuzumab for the treatment of patients with treatment-naïve chronic lymphocytic leukemia/small...

The Year in FDA Approvals

In the past year, the U.S. Food and Drug Administration (FDA) approved a record-breaking number of drugs, several of which were indicated for the...

SHARE